207 related articles for article (PubMed ID: 31114373)
1. A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab.
Hong J; Chen X; Gao W; Zhu S; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Fei X; Lin L; Shen K
Cancer Manag Res; 2019; 11():3371-3379. PubMed ID: 31114373
[No Abstract] [Full Text] [Related]
2. Absolute Lymphocyte Count Changes During Neoadjuvant Chemotherapy are Associated With Prognosis of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Patients.
Miyamoto N; Inoue H; Inui T; Sasa S; Aoyama M; Okumura K; Toba H; Hino N; Nishisho A; Yukishige S; Kawanaka T; Takizawa H; Tangoku A
Clin Breast Cancer; 2023 Apr; 23(3):e68-e76. PubMed ID: 36682907
[TBL] [Abstract][Full Text] [Related]
3. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
Araki K; Ito Y; Fukada I; Kobayashi K; Miyagawa Y; Imamura M; Kira A; Takatsuka Y; Egawa C; Suwa H; Ohno S; Miyoshi Y
BMC Cancer; 2018 Oct; 18(1):982. PubMed ID: 30326862
[TBL] [Abstract][Full Text] [Related]
4. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?
Ulas A; Avci N; Kos T; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
J BUON; 2015; 20(3):714-22. PubMed ID: 26214622
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer.
Patel DA; Xi J; Luo J; Hassan B; Thomas S; Ma CX; Campian JL
Breast Cancer Res Treat; 2019 Apr; 174(2):443-452. PubMed ID: 30604000
[TBL] [Abstract][Full Text] [Related]
6. Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 Inhibitors.
Kanaoka H; Nagahashi M; Atake Y; Hattori A; Bun A; Fukui R; Ozawa H; Fujimoto Y; Higuchi T; Natori K; Imamura M; Murase K; Takatsuka Y; Miyoshi Y
Anticancer Res; 2022 Oct; 42(10):4867-4878. PubMed ID: 36192009
[TBL] [Abstract][Full Text] [Related]
7. Baseline Lymphopenia: A Predictor Of Poor Outcomes In HER2 positive Metastatic Breast Cancer Treated With Trastuzumab.
Che YQ; Zhang Y; Wang D; Liu HY; Shen D; Luo Y
Drug Des Devel Ther; 2019; 13():3727-3734. PubMed ID: 31754298
[TBL] [Abstract][Full Text] [Related]
8. Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 Trial.
Tokunaga E; Miyoshi Y; Dozono K; Kawaguchi T; Toi M
Oncologist; 2024 Mar; 29(3):e319-e329. PubMed ID: 37971418
[TBL] [Abstract][Full Text] [Related]
9. High Systemic Immune-Inflammation Index Predicts Poor Survival in Patients with Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer Receiving Adjuvant Trastuzumab.
Jiang L; Fang J; Ding J
Cancer Manag Res; 2020; 12():475-484. PubMed ID: 32021460
[TBL] [Abstract][Full Text] [Related]
10. Absolute Lymphocyte Count as an Independent Prognostic Factor in Metastatic Breast Cancer: A Retrospective Study.
Sawa A; Bando H; Kamohara R; Takeuchi N; Terasaki A; Okazaki M; Iguchi-Manaka A; Hara H
Oncology; 2022; 100(11):591-601. PubMed ID: 36099888
[TBL] [Abstract][Full Text] [Related]
11. Utility of the Absolute Lymphocyte Count and Neutrophil/Lymphocyte Ratio for Predicting Survival in Patients with Metastatic Breast Cancer on Eribulin: A Real-World Observational Study.
Ueno A; Maeda R; Kin T; Ito M; Kawasaki K; Ohtani S
Chemotherapy; 2019; 64(5-6):259-269. PubMed ID: 32305977
[TBL] [Abstract][Full Text] [Related]
12. Monitoring trends in the absolute lymphocyte count and the neutrophil-to-lymphocyte ratio in patients with breast cancer receiving eribulin.
Su MX; Lin HW; Nguyen HTH; Lin TC; Chen CJ; Wang HC; Wu CT; Wu YC; He GY; Liu LC; Huang CH
BMC Cancer; 2024 Feb; 24(1):195. PubMed ID: 38347468
[TBL] [Abstract][Full Text] [Related]
13. Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy.
Ding N; Huang J; Li N; Yuan J; Wang S; Xiao Z
BMC Cancer; 2020 Mar; 20(1):235. PubMed ID: 32192443
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil-Lymphocyte Ratio and Absolute Lymphocyte Count as Prognostic Markers in Patients Treated with Curative-intent Radiotherapy for Non-small Cell Lung Cancer.
Punjabi A; Barrett E; Cheng A; Mulla A; Walls G; Johnston D; McAleese J; Moore K; Hicks J; Blyth K; Denholm M; Magee L; Gilligan D; Silverman S; Qureshi M; Clinch H; Hatton M; Philipps L; Brown S; O'Brien M; McDonald F; Faivre-Finn C; Hiley C; Evison M
Clin Oncol (R Coll Radiol); 2021 Aug; 33(8):e331-e338. PubMed ID: 33863615
[TBL] [Abstract][Full Text] [Related]
15. Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients.
Khunger M; Patil PD; Khunger A; Li M; Hu B; Rakshit S; Basu A; Pennell N; Stevenson JP; Elson P; Panchabhai TS; Velcheti V
PLoS One; 2018; 13(10):e0197743. PubMed ID: 30359383
[TBL] [Abstract][Full Text] [Related]
16. Improved prognosis of low baseline neutrophil-to-lymphocyte ratio is significantly exclusive in breast cancer patients with high absolute counts of lymphocytes.
Fujimoto Y; Ozawa H; Higuchi T; Miyagawa Y; Bun A; Imamura M; Miyoshi Y
Mol Clin Oncol; 2019 Feb; 10(2):275-284. PubMed ID: 30680208
[TBL] [Abstract][Full Text] [Related]
17. Elevated preoperative neutrophil-to-lymphocyte ratio predicts poor disease-free survival in Chinese women with breast cancer.
Hong J; Mao Y; Chen X; Zhu L; He J; Chen W; Li Y; Lin L; Fei X; Shen K
Tumour Biol; 2016 Mar; 37(3):4135-42. PubMed ID: 26490984
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of Pretreatment Lymphocyte-to-Monocyte Ratio and Development of a Nomogram in Breast Cancer Patients.
Yin Y; Zhang Y; Li L; Zhang S; Liu N; Yuan S
Front Oncol; 2021; 11():650980. PubMed ID: 34976782
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of haematologic parameter changes during treatment in cervical cancer patients treated with definitive chemoradiotherapy.
Yildirim BA; Guler OC; Kose F; Onal C
J Obstet Gynaecol; 2019 Jul; 39(5):695-701. PubMed ID: 31023114
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil-to-lymphocyte ratio correlates with prognosis and response to chemotherapy in patients with non-M3
Zhang Q; Yang Q; Weng Y; Huang Z; Chen R; Zhu Y; Dai K; Zhang S; Jiang S; Yu K
Transl Cancer Res; 2021 Feb; 10(2):1013-1024. PubMed ID: 35116428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
